Effects of Multiple Doses of CS-8080 in Healthy Volunteers

This study has been terminated.
(Safety concerns)
Sponsor:
Information provided by:
Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier:
NCT00796575
First received: November 21, 2008
Last updated: December 19, 2008
Last verified: December 2008
  Purpose

The main purposes of this study are to assess the safety and measure the pharmacokinetics and pharmacodynamics of CS-8080 in healthy volunteers.


Condition Intervention Phase
Healthy
Drug: CS-8080
Drug: placebo tablets
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled, Multiple Ascending Dose Study To Assess The Safety, Pharmacokinetics and Pharmacodynamics Of CS-8080 In Healthy Volunteers

Further study details as provided by Daiichi Sankyo Inc.:

Primary Outcome Measures:
  • Safety [ Time Frame: 21 days ] [ Designated as safety issue: No ]
  • plasma pharmacokinetics after multiple doses [ Time Frame: 16 days ] [ Designated as safety issue: No ]
  • effect on ABCA1 mRNA after multiple doses [ Time Frame: 16 days ] [ Designated as safety issue: No ]
  • effect on ABCG1 mRNA after multiple doses [ Time Frame: 16 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • effect on gene expression by microarray after multiple doses [ Time Frame: 16 days ] [ Designated as safety issue: No ]
  • effect on triglycerides following an oral fat load after multiple doses [ Time Frame: 16 days ] [ Designated as safety issue: No ]
  • effect on plasma lipids after multiple doses [ Time Frame: 16 days ] [ Designated as safety issue: No ]
  • effect on lipoproteins after multiple doses [ Time Frame: 16 days ] [ Designated as safety issue: No ]
  • effect on HDL particle distribution after multiple doses [ Time Frame: 16 days ] [ Designated as safety issue: No ]
  • effect on hepatic fat content after multiple doses [ Time Frame: 16 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: November 2008
Estimated Study Completion Date: April 2009
Estimated Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CS-8080
3 mg CS-8080, 10mg CS-8080, 20 mg CS-8080
Drug: CS-8080
CS-8080 1mg tablets, 3 tablets administered 1 times per day
Drug: CS-8080
CS-8080 5 mg tablets, 2 tablets administered 1 times per day
Drug: CS-8080
CS-8080 5 mg tablets, 4 tablets administered 1 times per day
Placebo Comparator: placebo
placebo
Drug: placebo tablets
placebo tablets matching active

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy men and/or women, aged 18 to 45 years inclusive.
  • WOCBP cannot be pregnant or nursing, must have been using a medically acceptable method of contraception for at least 3 months prior to study screening
  • All women must have a negative quantitative serum pregnancy test at screening, on Day -4, and within 24 hours before dosing.
  • Male subjects must agree not to donate sperm during the study and for 3 months after their last scheduled visit. Males must also agree to use a use a condom with spermicide whenever engaging in sexual activity for this period of time.
  • Body Mass Index (BMI) of 19 to 30 kg/m inclusive and weight <300 lbs.
  • Good health as determined by the absence of clinically significant deviation from normal, based on medical history, physical examination, laboratory reports, and 12-lead ECG, as deemed by the Investigator, prior to enrollment.
  • Able to understand and willing to comply with all study requirements, and willing to follow the study medication regimen.
  • Willing and able to give a written informed consent.
  • Negative urine test for drugs of abuse and alcohol at screening and check-in.
  • Negative result for HIV antibody, hepatitis B surface antigen, and hepatitis C antibody at screening.
  • Subjects must agree not to donate blood, plasma, platelets, or any other blood components during the study and for 4 weeks after the last dose.

Exclusion Criteria:

  • WOCBP is pregnant (as based on test results) or is breast feeding.
  • Subject is not using adequate contraceptive precautions.
  • Any history of drug abuse.
  • History of alcohol addiction during the 2 years prior to Day 1.
  • History of significant allergic response to any drug except penicillin, or known sensitivity to any of the products to be administered during dosing.
  • History or current evidence, as determined by the Investigator, of psychiatric or emotional problems which would invalidate giving informed consent or limit the ability of the subject to comply with study requirements.
  • History or current evidence of clinically significant cardiac, hepatic, renal, pulmonary, endocrine, neurologic, infectious, gastrointestinal (ie, any condition which may affect drug absorption), hematologic, or oncologic disease as determined by the Investigator after reviewing screening history, physical examination, laboratory test results, and 12-lead ECG.
  • History or current alcoholic or non-alcoholic liver disease or liver steatosis.
  • History of prostate disease or prostatitis.
  • Subjects with a history of congenital Long QT Syndrome (LQTS), a history of surviving a near-drowning episode, or a history of any form of syncope or loss of consciousness.
  • Subjects with QTcF interval duration >450 msec obtained as an average from the ECG machine readings on the triplicate ECG (3 readings not more than 2 minutes apart) taken at screening, after at least 10 minutes of quiet rest in a supine position.
  • Subjects with abnormal ECG waveform morphology on any of the ECGs from the screening triplicate that would preclude accurate manual measurement of the QT interval duration.
  • Need for any concomitant medication.
  • Prestudy medication use as specified in protocol.
  • Consumption of any food or beverages containing grapefruit from 7 days prior to Day 1 through study completion.
  • Consumption of foods or beverages containing alcohol from 24 hours before check-in through discharge from the clinic.
  • Blood donation or significant blood loss within the 56 days before Day -1.
  • Plasma donation within 7 days before Day -1.
  • Participation in another investigational new drug research study within the 30 days before Day 1.
  • Prior exposure to CS-8080.
  • Use of tobacco products or nicotine-containing products (including smoking cessation aids, such as gums or patches) within the 6 months before Day 1.
  • Relationship of the subject to the Investigator, any sub-investigator, pharmacist, study coordinator, or other staff directly involved in the conduct of the study, or employment by the Sponsor or contract research organization participating in the study.
  • Familial relationship with any other study participant.
  • Screening laboratory values outside the range of normal values deemed clinically significant by the Investigator. Serum lipid tests, triglycerides, cholesterol (LDL, HDL and total cholesterol), liver function tests (ALT, AST, GGT, total bilirubin, LDH and ALP) and PSA must not exceed the upper limit of normal without permission of the Sponsor. For males, testosterone, LH and FSH must be within normal limits.
  • Hemoglobin <12.0 g/dL at the screening visit.
  • Positive fecal occult blood test at screening.
  • Shift work, defined as any work shifts, either regular or irregular, precluding sleep during the hours of 10 pm and 6 am, within 1 week prior to Day -4, and no more than 2 works shifts per week meeting the above criteria from 4 to 1 week prior to Day -4.
  • Any of the following, if determined to render the subject ineligible for hepatic MRI scanning: pacemaker, aneurism clips, heart valve replacements, cochlear implants, neuro- or spine-stimulator, pessary (bladder support), body piercing that cannot be removed, metal slivers in eyes, shrapnel, hearing aid that cannot be removed, non-removable metal dental work or dentures, tattoos over 20 years old, IUD or penile implant. An X-ray may be required to assess eligibilty for the procedure.
  • History of claustrophobia or intolerance to MRI scanning procedures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00796575

Locations
United States, New Jersey
MDS Pharma Services
Neptune, New Jersey, United States, 07753
Sponsors and Collaborators
Daiichi Sankyo Inc.
  More Information

No publications provided

Responsible Party: Director Experimental Medicine, Daiichi Sankyo
ClinicalTrials.gov Identifier: NCT00796575     History of Changes
Other Study ID Numbers: CS8080-A-U102
Study First Received: November 21, 2008
Last Updated: December 19, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Daiichi Sankyo Inc.:
multiple ascending dose healthy volunteers
pharmacokinetics
pharmacodynamics

ClinicalTrials.gov processed this record on July 22, 2014